Passion for Innovation. Compassion for Patients.™ Daiichi Sankyo Europe GmbH

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

Lung Cancer

We seek to make a difference in lung cancer treatment

Lung cancer is the leading cause of cancer death among both men and women, and accounts for about one-fifth of all cancer deaths globally, with 80 to 85 percent classified as non-small cell lung cancer (NSCLC).1,2 For patients with metastatic disease, prognosis is particularly poor, as only 6 to 10 percent live beyond five years after diagnosis.Other common type of lung cancers are for example mesothelioma, chest wall tumors or small cell lung cancer of which the last is almost in all cases caused by cigarette smoking.4

A number of biomarkers have been studied in lung cancer, including KRAS, ALK (anaplastic lymphoma kinase), ROS1 or BRAF V600E mutation. Approximately 25 to 30 percent of lung cancers worldwide have an EGFR-activating mutation, and it is estimated that about 83 percent of all NSCLC tumors express the HER3 protein, which can be associated with an increased incidence of metastases, reduced survival and resistance to standard treatment.5,6,7 

To enable patients to further experience moments that matters together with their family and friends, we further develop lung cancer treatment and medication. This way we try to support further innovations in lung cancer and continuously increase the awareness for the topic.

References

1 World Health Organization. GLOBOCAN 2020. Lung Cancer Fact Sheet. January 2021.
2 American Cancer Society. About Lung Cancer. Types of Lung Cancer. January 2020.
3 Goldstraw P, et al. J Thorac Oncol. 2016; 11(1):39–51.
4 Lung Cancer Types | Johns Hopkins Medicine. [Accessed: October 2021]
5 Zhang YL, et al. Oncotarget. Vol. 7 No 49. 78985-78993.
6 Muller-Tidow C, et al. Cancer Res. 2005;65:1778-1772.
7 Scharpenseel, et al. Scientific Reports. 2019;9:7406.